Ireland
--:--IST
Latest
Clinical Trials in France / NCT05248477
Active, not recruiting Not applicable

Improve the Survival Without Morbidity of Extremely Preterm Infants (PREMEX)

NCT05248477 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-06-01
Last updated
2025-11-20

Condition(s) studied

NewbornExtreme PrematurityPretrm Infants

Investigational drug(s) / intervention(s)

Premex Protocol

Premex Protocol: This protocol presupposes stages during which staff are informed and trained. It is based on the following principles: * Administration of corticosteroid therapy to all eligible women, independent of the decision about active or palliative care * A prognostic evaluation in a non-emergency meeting of the obstetricians and neonatologists/pediatricians involved, no longer based only on gestational age, and enabling the team to provide consistent, consensual, and individualized information to parents; * A joint decision about the obstetric and neonatal (active or palliative) care to be proposed to parents at the end of this evaluation; * An interview with parents, also on non-emergency basis, to give them information about the child's prognosis and the management proposed, to answer their questions, and to obtain their opinion; * Management at birth consistent with that decided in consultation with the parents.

Study summary

The intervention proposed is a new organization of care, based on the EXPRIM (EXtrem PRematurity Innovative Management) protocol, involving early, standardized, and multidisciplinary management of women hospitalized for a risk of extremely preterm birth and their children. It will take place in each perinatal network for all pregnant women hospitalized between 22 and 26 weeks with a risk of preterm delivery.

Setting up the protocol requires taking into account the parents' time and timing issues, and its potential for change, to plan the implementation of the protocol, especially the degree of emergency of the situation and the probability of imminent delivery.

The follow-up collected for this study will take place:

* At D4 post-delivery: A questionnaire about the parents' experience of the information delivered and the decisions made will be given to and collected from the parents
* At Day 28, post-delivery: A questionnaire about the parents' experience of care for their child will be given to and collected from the mother and the co-parent.
* At the child's discharge from the hospital, or if he or she dies in the hospital:

* Collection of clinical data (principal endpoint) from data in the medical file.
* Data to measure practices and adherence to the intervention will be collected
* When the child reaches the corrected age of 2 years:

* a short questionnaire will be completed by the physician caring for the child at the corrected age of 2 years. The data collected will concern motor and sensory development, in particular, cerebral palsy, blindness, and deafness..
* Information about the child's development will also be collected with a questionnaire including a standardized assessment scale, he PARCA-R questionnaire (Parent Report of Children's Abilities-Revides), which the parents will complete.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: Mothers: * women hospitalized between 22 and 26 weeks for risk of preterm delivery with a fetus alive or dead at admission and with a delivery between 22 and 26 completed weeks * understanding of the French language by the woman or in the immediate entourage in charge of the child. Children: all newborns (live- and stillborn) delivered between 22 and 26 weeks. Exclusion Criteria * women who object to the use of their routine perinatal data, * women giving birth before 22 weeks and after 26 completed weeks. * woman to legal protection (subject protected by law under guardianship or curatorship) * Women undergoing a termination of pregnancy (TOP) for severe congenital anomaly or psycho-social contexte

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hôpital Cochin Paris France

More Assistance Publique - Hôpitaux de Paris trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05248477 on ClinicalTrials.gov ↗ ← All trials in France